48 results about "Diabetic Vascular Complications" patented technology

The invention discloses a new clause of a five membered heterocylic ring compounds of general formula I and its pharmaceutically or cosmetically acceptable salts, wherein R1, R2, R3, R4, R5, A, B, X and Y are as defined in the specification. The invention also discloses a process for preparation of these compound and their therapeutic and cosmetic applications particularly in the management of aging related and diabetic vascular complications. The compounds in question act by triple action of an AGE (Advanced Glycation Endproducts) breaker, AGE inhibitor and free radical scavenger which make them most suitable in different therapeutic and cosmetic applications. The invention also discloses pharmaceuticals and cosmetic compositions comprising these compounds and method of treatment of diseases caused by accumulation of AGE and / or free radicals in the body cells.

The present invention relates to a combination, such as a combined preparation or pharmaceutical composition comprising: (a) compound of formula (I), and / or (II) or a pharmaceutically acceptable salt thereof; (b) at least one therapeutic agent selected from the group consisting of: an antihypertensive agent; an antidiabetics agent; a hypolipidemic agent; an antiplatelet agent; an antiobesity agent; an antithrombotic agent; an agent for diabetic vascular complications; and an agent for treatment of heart failure; or a pharmaceutically acceptable salts thereof, optionally in presence of a pharmaceutically acceptable carrier for separate, simultaneous or sequential use. The present invention also relates to a use of such combination for the treatment of mammal including human being. R1, R2, R3, R1, R2, R3, R4, R5, X, Y, A and B and m are as defined in the specification.

The present invention relates to the discovery that CTGF is a diagnostic marker indicative of increased risk for development and progression of vascular disease.

A compound which has excellent LCAT activation effects, is useful as an active ingredient of a therapeutic or preventive agent for arteriosclerosis, arteriosclerotic cardiovascular disease, coronary heart disease (including heart failure, myocardial infarction, angina, cardiac ischemia, cardiovascular disorder, and angioplastic restenosis), cerebrovascular disease (including cerebral stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complication), dyslipidemia, low HDL cholesterol, high HDL cholesterol, or kidney disease, in particular, of an anti-arteriosclerosis agent, and is represented by general formula (I) (I) [In the formula, R is an aryl group which may be substituted or a heteroaryl group which may be substituted, and R1 is a hydrogen atom or a hydroxyl group.] or a pharmacologically acceptable salt thereof (as shown in the description).

The invention discloses a new clause of a five membered heterocylic ring compounds of general formula Iand its pharmaceutically or cosmetically acceptable salts, wherein R1, R2, R3, R4, R5, A, B, X and Y are as defined in the specification. The invention also discloses a process for preparation of these compound and their therapeutic and cosmetic applications particularly in the management of aging related and diabetic vascular complications. The compounds in question act by triple action of an AGE (Advanced Glycation Endproducts) breaker, AGE inhibitor and free radical scavenger which make them most suitable in different therapeutic and cosmetic applications. The invention also discloses pharmaceuticals and cosmetic compositions comprising these compounds and method of treatment of diseases caused by accumulation of AGE and / or free radicals in the body cells.

A pharmaceutical composition that includes a carbamoyloxy arylalkanoyl arylpiperazine compound SERUM CHOLESTEROL and effectively prevents or treats diabetic nephropathy, diabetic neuropathy, diabetic vascular complications, hyperlipidemia, coronary artery disease, or inflammation.

The present invention provides a method for treating diabetic vascular complications including administering to a subject in need thereof a therapeutically effective amount of an extract product of a Dioscorea species. The extract product preferably is prepared by a process which involves (a) extracting a tuber of the Dioscorea species with an alcohol-based solvent in the presence of an acetic acid solution to form an extract composition, (b) subjecting a resultant product obtained in step (a) to obtain a soluble fraction, and (c) removing solvent from the soluble fraction obtained in step (b) to obtain the extract product.

The invention belongs to the technical field of biology and diagnosis, and relates to a receptor of a definite, effective and visualized platelet reactivity biomarker P2Y12 and an application thereof for diagnosing and predicting the II-type diabetic vascular complication risk. The platelet activation biomarker P2Y12 can detect expression levels of platelet through fluorescent quantitative polymerase chain reaction (PCR), Western blot, enzyme linked immunosorbent assay (ELISA), flow cytometry, UV spectrophotometry-near infrared spectrometry, high performance liquid chromatography, colorimetry, a mass spectrum identification method and the like and detect content of P2Y12 in whole blood. The invention also provides a method of biomarker P2Y12 for diagnosing and predicting vascular complication of subjects as well as a medicine for treating II-type diabetic vascular complication and a screening method of the medicine. The invention further provides an intervene plane for individualizing P2Y12 inverse agonist and accurately treating the vascular complication of II-type diabetic patients.

The present invention discloses an application of a double-sugar chain hederin compound in preparation of a drug for preventing vascular endothelial cell inflammatory injury. The compound can alleviate the vascular endothelial cell inflammatory injury by directly inhibiting adsorption of inflammatory factors and adhesion molecules, and regulating a NF-kappa-B signaling pathway and other various pathways, and plays a protection function of the vascular endothelial cell inflammatory injury. The application of the double-sugar chain hederin in the preparation of the drug for preventing the vascular endothelial cell inflammatory injury s is first disclosed, and the double-sugar chain hederin compound is rich in raw material source and mature in preparation method, and has good value in development of drugs for treating vascular endothelial cell inflammatory injury related acute lung injury, kidney injury, pyohemia, atherosclerosis, vascular complications of diabetes, etc.

A compound represented by the general formula (I) or a pharmacologically acceptable salt thereof has an excellent LCAT-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-HDL-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein R is an optionally substituted aryl group or an optionally substituted heteroaryl group.

The invention provides a preparation method of cinchonain Ib. In the method, alcohol extracts of roots, fruits, stems and / or leaves of rosaceous plants, vitaceous vitis plants and smilacaceous plants are used as raw materials, and the raw materials are subjected to multiple liquid chromatographic enrichment and refining to obtain high-purity cinchonain Ib. The invention also provides application of cinchonain Ib in the preparation of drugs for preventing and treating diabetics or diabetic vascular complications, and a pharmaceutical composition comprising cinchonain Ib. The cinchonain Ib has the effect of lowering blood lipid in diabetic rats, has good synergy in controlling the progress of diabetic vascular complications, helps prevent and control metabolic syndromes so that the cinchonain Ib is more significantly advantageous in preventing and treating diabetic vascular complications, is efficient and nontoxic and high in safety and accordingly has a promising application prospect in the clinical prevention and treatment of diabetic vascular complications.

The invention discloses novel compounds of the pyridinium series useful for the management of diabetes and aging-related vascular complications, including kidney disease, nerve damage, atherosclerosis, retinopathy, dermatological disorders and discoloration of teeth, by breaking preformed AGE, of general formula (I), or pharmaceutically acceptable salts thereof, wherein, R1, R2, R3, X and m are as defined in the specification. The invention also discloses, method for preparation of the novel compounds of the series and pharmaceutical composition having one or more compounds as defined above as active ingredients. The invention further discloses a method of treatment of a diabetic patient by administering the compounds as defined above, either singly or in combination with drugs for antidiabetic therapy.

A compound represented by the general formula (I) or a pharmacologically acceptable salt thereof has an excellent LCAT-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-HDL-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein R is an optionally substituted aryl group or an optionally substituted heteroaryl group.

The invention discloses novel compounds of the pyridinium series useful for the management of diabetes and aging-related vascular complications, including kidney disease, nerve damage, atherosclerosis, retinopathy, dermatological disorders and discoloration of teeth, by breaking preformed AGE, of the general formula I, or pharmaceutically acceptable salts thereof, wherein, R1, R2, R3, X and m are as defined in the specification. The invention also discloses, method for preparation of the novel compounds of the series and pharmaceutical composition having one or more compounds as defined above as active ingredients. The invention further discloses a method of treatment of a diabetic patient by administering the compounds as defined above, either singly or in combination with drugs for antidiabetic therapy.

The present invention has discovered that connective tissue growth factor (CTGF) can be used as a diagnostic marker for the development and increased risk of progression of vascular disease.

The invention relates to the new application field of composition of red yeast rice and ginkgo leaves in the aspect of controlling diabetic complications, belonging to the fields of medicines and health foods. In order to solve the technical problems, the invention provides the application of the composition of red yeast rice and ginkgo leaves in the aspect of controlling diabetic complications. The composition of red yeast rice and ginkgo leaves has remarkable effects in controlling diabetic complications such as dyslipidemia, diabetic vascular complications, diabetic cardio-cerebrovascular diseases and diabet acompanied by coronary heart disease.

The invention discloses a new application for alisol B autophagy revulsive for treating diabetic and vascular complication, and the application in medicine. The invention through the experiment methods of electron microscope transmission, immunofluorescence testing, Westernblot, and more, fully proves the functions of alisol B in controlling the autophagic disorders of human kidney tubular epithelial cells, vascular endothelial cells, retinal cells, and cardiac muscle cells caused by advanced glycated end products (AGEs). The invention discovers the marker and action mechanism of alisol B inducer cell autophagy. Therefore, the proposal applies alisol B in the treatments of autophagy action mechanism related diseases, and particularly has broad application prospects in diabetics induced by autophagic disorders and in treatments of vascular complications as well as medicine developments.

The present invention provides a method for treating diabetic vascular complications including administering to a subject in need thereof a therapeutically effective amount of an extract product of a Dioscorea species. The extract product preferably is prepared by a process which involves (a) extracting a tuber of the Dioscorea species with an alcohol-based solvent in the presence of an acetic acid solution to form an extract composition, (b) subjecting a resultant product obtained in step (a) to obtain a soluble fraction, and (c) removing solvent from the soluble fraction obtained in step (b) to obtain the extract product.

The present invention discloses an application of gentiopicroside to the preparation of medicines for lowering blood sugar and / or improving diabetic vascular complications, and an application of gentiopicroside to the preparation of medicines for reducing blood fat. The invention also discloses a method for extracting gentiopicroside. The invention proves that gentiopicroside can obviously reduceglycometabolism indexes such as blood sugar, glycosylated hemoglobin and serum protein of diabetic model mice, regulate the abnormality of blood fat and oxidative stress index of the model mice, and obviously improve the abnormality of renal function, renal tissue pathology and inflammatory fibrosis components of the model mice. Moreover, the gentiopicroside has good effect on improving LDL-C and24-hour urine protein. Consequently, the gentiopicroside is a traditional Chinese medicine monomer medicament which has the potential of reducing blood sugar and comprehensively improving diabetic nephropathy.

The invention relates to application of complex of parietic acid or parietic acid compounds and arginine in preparation of medicines for treating vascular complications of diabetes. The vascular complications of diabetes mean diabetic great vascular complications or diabetic microangiopathy and comprise diabetic testopathy, sexual debility of diabetic complications (comprising diabetic testopathy and diabetic impotence), diabetic retinopathy and diabetic neuropathy. The complex is abbreviated as Dajingsuan which is a novel crystallized compound and enters into body to release parietic acid and arginine; the solubility of parietic acid is changed, so that the bioavailability is improved and the stability is good. A novel structural characteristic is endowed to a parent compound of parietic acid; Dajingsuan enters into body to release parietic acid and arginine, so that the function of parietic acid which inhibits inflammatory factors: NFkB, TNF alpha, ROS, EGF and the like to regulate the endothelin system is exerted.

The present invention relates to a use of sirtuin 1 (SIRT1) in preparation of drugs for prevention of diseases caused by endothelial dysfunction. Specifically, the present invention relates to a use of the SIRT1 in preparation of drugs for prevention and / or treatment of endothelial dysfunctions of mammals including human, and prevention and / or treatment of diabetic vascular complications of mammals including human.

The invention discloses the application of a class of double sugar chain hedera saponin compounds in the preparation of drugs for resisting inflammatory injury of vascular endothelial cells. This kind of compound alleviates the inflammatory injury of endothelial cells by directly inhibiting the adsorption of inflammatory factors and adhesion molecules, regulating NF-κB signaling pathway and other ways, and plays a protective role in the inflammatory injury of vascular endothelial cells. The application of this type of double sugar chain hedera saponins in the preparation of drugs against inflammatory injury of vascular endothelial cells is disclosed for the first time, and the sources of raw materials are abundant and the preparation methods are mature. It has good value in the development of drugs for the treatment of toxicity, atherosclerosis and diabetic vascular complications.

The present invention provides a method for treating diabetic vascular complications including administering to a subject in need thereof a therapeutically effective amount of an extract product of a Dioscorea species. The extract product preferably is prepared by a process which involves (a) extracting a tuber of the Dioscorea species with an alcohol-based solvent in the presence of an acetic acid solution to form an extract composition, (b) subjecting a resultant product obtained in step (a) to obtain a soluble fraction, and (c) removing solvent from the soluble fraction obtained in step (b) to obtain the extract product.

A compound represented by the general formula (I) or a pharmacologically acceptable salt thereof has an excellent LCAT-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-HDL-cholesterolemia, hyper-LDL-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein R is an optionally substituted aryl group or an optionally substituted heteroaryl group, and R1 is a hydrogen atom or a hydroxy group.

The invention relates to a pharmaceutical composition containing a sugar reducing medicine, aspirin and folic acid, wherein the sugar reducing medicine is one of biguanide, sulfonylurea, thiazolidinedione, alpha-glycoside inhibitor or dipeptidyl peptidase IV (DPP-4) inhibitor medicines; and the aspirin content is preferably 50-150mg while the folic acid content is preferably 0.4-1.2mg. The invention also relates to an application of the composition in preparing a diabetes treatment medicine. A medicine prepared from the pharmaceutical composition provided by the invention has the beneficial effects of preventing or relieving vascular complications of diabetes on the basis of effectively reducing blood sugar, and thus is a more suitable anti-diabetic medicine.

The invention relates to an indolinone derivative or pharmaceutically acceptable salt, stereisomer, tautomer, solvate and predrug thereof. The compound disclosed by the invention has an excellent LCATactivation effect, is capable of remarkably increasing the HDL level and therefore can be used as an effective component in a treating agent or a prevention agent for coronary heart diseases (including heart failure, myocardial infarction, angina pectoris, myocardial ischemia, cardiovascular disorders and angiogenic restenosis), arteriosclerosis, arteriosclerotic heart disease, cerebrovascular diseases (including stroke and cerebral infarction), peripheral blood vessel diseases (including diabetic vascular complications), dyslipidemia, low HDL cholesteremia, high LDL cholesteremia or kidney diseases.

A crystal of a compound represented by the general formula (I) or a pharmacologically acceptable salt thereof has an excellent LCAT-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-HDL-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein R1 is a hydrogen atom or a hydroxy group, and R is a 2-(trifluoromethyl)pyrimidin-5-yl group or a 5-(trifluoromethyl)pyrazin-2-yl group.

The invention discloses a new application of an alginate sulfuric ester, which is the application of the alginate sulfuric ester in preparing drugs for preventing and treating diabetes and vascular diseases. The alginate sulfuric ester optimizes low molecular weight alginate with the weight-average molecular weight of 3-30 KD and comprises the following materials in percentage by weight: 25%-35% of fucose and 25%-35% of sulfate; and the low molecular weight alginate sulfuric ester is obtained by degrading alginate sulfuric ester. Shown by I type diabetes model rat in vivo animal experiments, in vitro tissue experiments and protein level research, the alginate sulfuric ester has certain therapeutic action on the diabetes and vascular complications, and the mechanism of the alginate sulfuric ester is related to the effects of reducing the oxidative stress level of the diabetes and the epoxidase-2 expression of vascular smooth muscles so as to influence the forming of prostaglandins substances.

The invention relates to an application of a rhein-arginine complex in the preparation of medicines for treating diabetic nephropathies. The medicines for treating diabetic nephropathies are medicines for improving tiny amounts of proteinuria, creatinine and non-protein nitrogen. The medicines are novel medicines having a good safety, have better medicine effects than traditional treatment medicines and treatment methods, and allow the examples of a traditional Chinese medicinal super-molecule technology in the reconstruction of important effective components to be started and the researches and applications of the super-molecule technology in traditional Chinese medicines innovated medicines to be enlarged. The rhein-arginine complex is called rhein-arginine for short, is a new crystalline compound, and releases rhein and arginine after the rhein-arginine enters a body; and the dissolvability of rhein is changed, and the bioavailability is improved; the stability is good; a rhein parent compound is endowed with a new structural characteristic; and the rhein-arginine can inhibit a plurality of inflammatory factors comprising NFkappaB, TNFalpha, ROS, EGF and the like, can regulate the endothelin system and can improve endothelial cells.